Pouchitis
46
7
8
17
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
15.2%
7 terminated out of 46 trials
70.8%
-15.8% vs benchmark
26%
12 trials in Phase 3/4
41%
7 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 17 completed trials
Clinical Trials (46)
Etrasimod as Prevention of Pouchitis
Emerging Indications for Hyperbaric Oxygen Treatment
ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch Surgery
Fecal Microbiota Transplant for Patients With Chronic Pouchitis
Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis
Fecal Microbiota Transplantation for Pouchitis
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
CLF065 for Chronic Pouchitis
GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis
Stem Cells for the Treatment of Pouchitis
The Role of Secondary Bile Acids in Intestinal Inflammation
the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
Exploring the Influence of Trptophan on the Treatment of Pouchitis
Stelara fOr ChRonic AntibioTic rEfractory pouchitiS
Efficacy of Liraglutide Therapy in Patients With IPAA
Inflammatory Bowel Diseases Remission Registry
Tofacitinib For Treatment Of Chronic Pouchitis
Assessment of Patients With Acute Pouchitis Treated With Antibiotics